|
Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria |
Apr 2025 |
Hamostaseologie |
Myeloproliferative Neoplasms (MPN), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Therapy-related myelodysplastic syndromes in the genomics era |
Jun 2023 |
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
|
Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS |
Jun 2020 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Therapy for lower-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents |
Apr 2023 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
Dec 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes |
May 2023 |
Frontiers in Oncology |
Aplastic Anemia |
|
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
Oct 2019 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
The Problem of TP53-Mutant MDS/AML |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome |
Mar 2025 |
BioDrugs |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
